The aim of this study was to investigate the impact of active TGF-β signaling on recurrence risk in early-stage breast cancer, including ipsilateral breast tumor recurrence (IBTR) and all recurrence types, with a particular focus on the benefit of radiotherapy (RT), using nuclear pSMAD2 as a biomarker. Here, TGFB1 is linked to breast cancer.